Médica Sur S.A.B. de C.V. stock (MXP606391060): Mexican hospital operator reports solid 2024 results

Médica Sur S.A.B. de C.V., the Mexican hospital and diagnostics group, has reported higher full?year 2024 revenue and profit. The stock remains a niche healthcare exposure for international and US investors interested in the Mexican private hospital market.

Médica Sur S.A.B. de C.V., a private hospital and diagnostics provider based in Mexico, recently published its audited financial results for the year 2024, showing year?on?year growth in revenue and net income, according to the company’s annual report dated 03/14/2025 on the Mexican Stock Exchange website and its investor relations page (Bolsa Mexicana de Valores as of 03/14/2025 and Médica Sur investor relations as of 03/14/2025).

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Medica Sur
• Sector/industry: Healthcare services, hospitals, diagnostics
• Headquarters/country: Mexico City, Mexico
• Core markets: Private hospital and diagnostic services in Mexico
• Key revenue drivers: Inpatient and outpatient hospital care, laboratory and imaging services
• Home exchange/listing venue: Bolsa Mexicana de Valores (ticker: MEDICA)
• Trading currency: Mexican peso (MXN)

Médica Sur S.A.B. de C.V.: core business model

Médica Sur operates a network centered around its flagship hospital complex in southern Mexico City, providing specialized medical care, surgery, intensive care, oncology and other high?complexity services. The company also offers outpatient consultations and a range of diagnostic procedures, including imaging and clinical laboratory tests, targeted at middle? and high?income patients. It positions itself as a premium private healthcare provider in the Mexican market.

The business model focuses on combining hospital operations with ancillary services that support patient care and create additional revenue streams. These services include diagnostic imaging, laboratory analysis, pathology and preventive health check?ups. Revenue is generated through a mix of direct out?of?pocket payments, corporate contracts and agreements with private insurers, which is common for private hospital groups in Mexico. This model has allowed Médica Sur to expand its service offering without relying on a large publicly funded payer base.

In addition to traditional hospital stays, Médica Sur emphasizes ambulatory and minimally invasive procedures, which can improve capacity utilization and margins. Shorter stays can increase patient throughput in high?demand specialties such as cardiology and oncology. The group also benefits from a growing demand for high?quality private healthcare in Mexico City, driven by demographic aging and rising income levels in parts of the population, according to industry overviews on the Mexican Stock Exchange profile page for Médica Sur (Bolsa Mexicana de Valores as of 02/28/2025).

Main revenue and product drivers for Médica Sur S.A.B. de C.V.

In its 2024 annual report published on 03/14/2025, Médica Sur stated that the bulk of revenue comes from hospital services, including room and board, operating room use, intensive care and specialist medical fees. Diagnostic services, such as laboratory tests and imaging, represent a second key pillar of the business, providing both stand?alone revenue and supporting clinical decisions inside the hospital (Médica Sur investor relations as of 03/14/2025).

The company noted that patient volumes in several specialties, including oncology and cardiology, increased in 2024 as elective procedures normalized after earlier pandemic disruptions, contributing to higher bed occupancy rates. Revenue from intensive care units and high?complexity surgeries generally carries higher average billing per patient, which can support overall profitability when capacity is well utilized. Management highlighted in the report that efficiency measures, such as better scheduling and operating room management, also contributed to improved operating margins during the period ended 12/31/2024 (Bolsa Mexicana de Valores as of 03/14/2025).

Diagnostics, including laboratory and imaging services offered both to inpatients and outpatients, form another important revenue driver. These services often have lower fixed costs relative to some high?complexity surgical procedures and can be scaled through extended operating hours and partnerships with physicians. Médica Sur’s 2024 results commentary indicated that investments in new imaging equipment and laboratory automation during 2023 and 2024 helped handle larger test volumes, which in turn supported revenue growth without a proportional increase in personnel costs, according to the annual report released 03/14/2025 (Médica Sur investor relations as of 03/14/2025).

Conclusion

Médica Sur S.A.B. de C.V. offers investors exposure to the Mexican private hospital and diagnostics market, with its 2024 annual report dated 03/14/2025 showing growth in revenue and net income versus the prior year. The company’s focus on high?complexity hospital services, combined with diagnostics, provides multiple revenue streams but also requires ongoing capital expenditure and careful cost control. For US investors, the stock represents a relatively small, peso?denominated healthcare name listed on the Mexican Stock Exchange, which can add geographic and sector diversification but also introduces currency and market?structure considerations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.